Vertex Pharmaceuticals: Strong Buy Rating Driven by Suzetrigine Approval and Promising Market Prospects
Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating on January 31.Maximize Your ...
What's Happening With VRTX Stock?
With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...
Jim Cramer on Vertex Pharmaceuticals Incorporated (VRTX)’s Suzetrigine: ‘I Don’t See A Lot Of Upside Because That Was The Drug Of The Future For Vertex’
We recently compiled a list of the Jim Cramer Shed Light on These 9 Stocks. In this article, we are going to take a look at ...
Evercore ISI Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Evercore ISI analyst Liisa Bayko maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) on January 31 and set a price ...
Vertex Pharmaceuticals (NASDAQ:VRTX) Lowered to “Equal Weight” Rating by Wells Fargo & Company
Wells Fargo & Company downgraded shares of Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) from an overweight rating to an equal weight rating in a report issued on Thursday, MarketBeat.com reports ...
Vertex wins reimbursement deal for CRISPR-partnered sickle cell therapy in England
Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...
Vertex Pharmaceuticals price target raised to $433 from $430 at Scotiabank
Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $433 from $430 and keeps a Sector Perform rating on the shares. Vertex’s suzetrigine, branded Journavx, was recently ...
Vertex Pharmaceuticals’ (VRTX) “Hold” Rating Reiterated at Needham & Company LLC
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “hold” rating reaffirmed by Needham & Company LLC in a report released on Friday,Benzinga reports. A number of other research ...